Radiosensitivity of HPV-related Tumors: Towards a Genomic Approach
NCT ID: NCT06321627
Last Updated: 2024-03-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2023-04-14
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Multimodality Treatments of HPV-related Lesions of the Female Genital Tract
NCT05938192
Adjuvant VaccInation After Conization for the Treatment for CervicAL Dysplasia
NCT06611020
Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical Lesions
NCT04211103
Early Warning Model of Susceptibility and High-risk Population of Cervical Cancer Related to HPV
NCT04974424
HPV Infections, Cancer of the Vulva and Therapeutical Success
NCT03082950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim is to:
1. investigate the role of Cl2 in non-oropharyngeal HPV-related tumors, and
2. compare the Radiation Sensitivity Index (RSI) values of HPV-related tumors in patients who responded to radiotherapy (responders) with those of patients with radioresistant tumors (non-responders).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with HPV-related tumors
Patients with HPV-related tumors of the oropharynx, cervix, and anus
Radiation therapy as curative treatment
Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiation therapy as curative treatment
Radiation therapy as curative treatment (exclusive, post-operative, with or without chemotherapy) for HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of HPV-related squamous cell carcinomas of the oropharynx, uterine cervix, and anus
* Curative intent radiation therapy (exclusive, post-operative, with or without chemotherapy)
* Availability of pre-radiation therapy biopsy sample
* No diagnosis of solid neoplasms and/or hematologic malignancies in the previous 5 years
* Possibility of retrospective and prospective data collection and anonymous submission to the referring center of clinical data related to the patient, pathology, and treatment characteristics (including radiation treatment plan in RT.dose format)
* Ability to obtain written informed consent for the use of data anonymously for research purposes
Exclusion Criteria
* Patients with local and/or locoregional recurrence
* Patients with synchronous distant metastases at diagnosis
* Patients previously treated with oncologic therapies for tumors of the same anatomical site
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
European Institute of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Daniela Alterio
Role: PRINCIPAL_INVESTIGATOR
European Institute of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
European Institute of Oncology
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Daniela Alterio, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IEO 1811
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.